Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System (Q39025640)

8 September 2017

Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System (English)

1 reference

8 September 2017

0 references

Jennifer B Lai

1

1 reference

8 September 2017

Maxwell A Witt

2

1 reference

8 September 2017

Mary Patricia Pauly

3

1 reference

8 September 2017

Joanna Ready

4

1 reference

8 September 2017

Michael Allerton

5

1 reference

8 September 2017

Suk Seo

6

1 reference

8 September 2017

David J Witt

7

1 reference

8 September 2017

11 January 2017

1 reference

8 September 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

Drugs

1 reference

8 September 2017

77

1 reference

8 September 2017

3

1 reference

8 September 2017

313-318

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-016-0684-y

8 September 2017

0 references

cites work

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Trials and tribulations of non-inferiority: the ximelagatran experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Utilization of FibroScan in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Influence of provider experience on antiretroviral adherence and viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0684-Y

Generalizability of the results of randomized trials

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28078644

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-016-0684-Y

1 reference

8 September 2017

1 reference